How do you treat metastatic adenocarcinoma of the ampulla of Vater?
Answer from: Medical Oncologist at Academic Institution
True adenocarcinoma of the ampulla of Vater is an extremely rare cancer of the GI tract (<5 pts per million). Consequently, data is mostly derived from retrospective studies or large databases with few clinical trials available, especially with locally advanced and metastatic disease. I pers...
Comments
Medical Oncologist at Johns Hopkins University School of Medicine Thanks to @Nguyen H. Tran for such a thorough and ...
Medical Oncologist at NYU Grossman School of Medicine Agree with @Daniel A. Laheru. We tend to factor in...
Medical Oncologist at Johns Hopkins University School of Medicine Thanks @Kristen R. Spencer.
Medical Oncologist at Virginia Cancer Spclsts PC What about adjuvant care in these patients? Do you...
Answer from: Medical Oncologist at Academic Institution
Given its rarity, ampullary adenocarcinoma has often been grouped with other tumor types, such as biliary tract and small bowel cancers in prospective clinical studies (Valle et al., NEJM 2010; Overman et al., JCO 2009). As such, the optimal systemic treatment regimen has been debated and there are ...
Answer from: Medical Oncologist at Academic Institution
In the resected setting: it would be prudent to ask the surgeon and pathologist about ampullary vs peri-ampullary cancer. Prognosis and treatment are different for both entities and also for subtype. As discussed above, there is not much data. Most oncologists tend to use mFOLFIRINOX or pancreatic t...
Answer from: Medical Oncologist at Community Practice
I would think the treatments of both are becoming progressively similar; mFOLFIRINOX and FOLFOXIRI are virtually the same drugs and have proven the most active in the 2 individual types.
I would not favor a gemcitabine approach: there is activity, but more desirable outcomes can be reached with alt...
Thanks to @Nguyen H. Tran for such a thorough and ...
Agree with @Daniel A. Laheru. We tend to factor in...
Thanks @Kristen R. Spencer.
What about adjuvant care in these patients? Do you...